AC
IOVA icon

Apogem Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Apogem Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,132
Closed -$521K – 191
2021
Q3 		$521K Buy
21,132
+10,583
+100% +$249K 0.33% 105
2021
Q2 		$274K Buy
+10,549
New +$274K 0.18% 151

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Apogem Capital's IOVA Position: Q4 2021 in Review

Apogem Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 21,132 shares — an estimated $521K sold.

Apogem Capital first reported a position in IOVA in Q2 2021 and held it in 2 quarters. The position peaked at $521K in Q3 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Apogem Capital reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Apogem Capital sold 21,132 Iovance Biotherapeutics shares in Q4 2021, an estimated $521K.
  • Apogem Capital first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Apogem Capital's Iovance Biotherapeutics position peaked at $521K in Q3 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.